Undergraduate Degree

  • University of Scranton , 2009 , Scranton , PA

Medical School

  • Jefferson Medical College , 2013 , Philadelphia , PA


  • Boston Children's Hospital , 2014 , Boston , MA


Pediatric Neurology
  • Boston Children's Hospital , 2018 , Boston , MA


Epilepsy/Clinical Neurophysiology
  • Boston Children's Hospital , 2019 , Boston , MA


  • Boston Children's Hospital , 2020 , Boston , MA

Philosophy of Care

I am continually in awe of the resilience of my patients and their families. It is an honor to be a part of their team. Each day, I strive to do my best in optimizing my patients’ care and contributing to novel therapies for children with epilepsy and autoimmune disease in the future.


After child neurology residency, Dr. Stredny completed fellowship training in epilepsy and neuro-immunology at Boston Children's Hospital before joining as faculty. Her clinical practice specializes in both pediatric epilepsy/seizures and autoimmune diseases of the brain and spinal cord. She is particularly interested in the overlap between these two specialties, when seizures are caused by an abnormal immune system and treated with immunotherapy. Her clinical research focuses on these disorders in which we think autoimmunity or inflammation may contribute to the generation of seizures, including Rasmussen encephalitis, febrile infection-related epilepsy syndrome (FIRES), autoimmune encephalitis, and Landau-Kleffner syndrome.


  • American Board of Psychiatry and Neurology, Child and Adolescent Neurology
  • American Board of Psychiatry and Neurology, Clinical Neurophysiology


Publications powered by Harvard Catalyst Profiles

  1. Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort). Epilepsia. 2021 Jul; 62(7):1629-1642. View abstract
  2. Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop. Epilepsia Open. 2021 03; 6(1):62-72. View abstract
  3. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES). Child Neurol Open. 2020 Jan-Dec; 7:2329048X20979253. View abstract
  4. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 2020 12; 7(12):2467-2474. View abstract
  5. Magnetic resonance imaging-guided laser-induced thermal therapy for functional hemispherotomy in a child with refractory epilepsy and multiple medical comorbidities. J Neurosurg Pediatr. 2020 Oct 23; 1-6. View abstract
  6. Seizure-related injuries in inadequately treated epilepsy patients: A case-control study. Seizure. 2020 Dec; 83:17-20. View abstract
  7. Posterior-onset Rasmussen's encephalitis with ipsilateral cerebellar atrophy and uveitis resistant to rituximab. Epilepsy Behav Rep. 2020; 14:100360. View abstract
  8. Pharmacotherapy for Pediatric Convulsive Status Epilepticus. CNS Drugs. 2020 01; 34(1):47-63. View abstract
  9. Baseline and outcome assessment in pediatric status epilepticus. Seizure. 2019 May; 68:52-61. View abstract
  10. Towards acute pediatric status epilepticus intervention teams: Do we need "Seizure Codes"? Seizure. 2018 May; 58:133-140. View abstract
  11. Autoimmune Movement Disorders in Children. Semin Pediatr Neurol. 2018 04; 25:92-112. View abstract
  12. Rescue Medications in Epilepsy Patients: A Family Perspective. Seizure. 2017 Nov; 52:188-194. View abstract
  13. Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatr Neurol. 2016 09; 62:66-70. View abstract
  14. An improved phenylarsine oxide-affinity method identifies triose phosphate isomerase as a candidate redox receptor protein. Neurochem Res. 2010 Feb; 35(2):306-14. View abstract
  15. Oxidative inhibition of protein phosphatase 2A activity: role of catalytic subunit disulfides. Neurochem Res. 2007 Nov; 32(11):1957-64. View abstract